Abstract

Cancers infiltrated with T-cells are associated with a higher likelihood of response to PD-1/PD-L1 blockade. Counterintuitively, a correlation between epithelial–mesenchymal transition (EMT)-related gene expression and T-cell infiltration has been observed across tumor types. Here we demonstrate, using The Cancer Genome Atlas (TCGA) urothelial cancer dataset, that although a gene expression-based measure of infiltrating T-cell abundance and EMT-related gene expression are positively correlated, these signatures convey disparate prognostic information. We further demonstrate that non-hematopoietic stromal cells are a major source of EMT-related gene expression in bulk urothelial cancer transcriptomes. Finally, using a cohort of patients with metastatic urothelial cancer treated with a PD-1 inhibitor, nivolumab, we demonstrate that in patients with T-cell infiltrated tumors, higher EMT/stroma-related gene expression is associated with lower response rates and shorter progression-free and overall survival. Together, our findings suggest a stroma-mediated source of immune resistance in urothelial cancer and provide rationale for co-targeting PD-1 and stromal elements.

Details

Title
EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
Author
Wang, Li 1 ; Saci, Abdel 2 ; Szabo, Peter M 2 ; Chasalow, Scott D 2 ; Castillo-Martin, Mireia 3 ; Domingo-Domenech, Josep 4 ; Siefker-Radtke, Arlene 5 ; Sharma, Padmanee 5 ; Sfakianos, John P 6 ; Gong, Yixuan 7 ; Dominguez-Andres, Ana 4 ; Oh, William K 7 ; Mulholland, David 7 ; Azrilevich, Alex 2 ; Hu, Liangyuan 8 ; Cordon-Cardo, Carlos 3   VIAFID ORCID Logo  ; Salmon, Hélène 9 ; Bhardwaj, Nina 7 ; Zhu, Jun 10   VIAFID ORCID Logo  ; Galsky, Matthew D 7 

 Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Sema4, A Mount Sinai venture, Stamford, CT, USA 
 Bristol-Myers Squibb, Princeton, NJ, USA 
 Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA 
 Departments of Oncology and Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA 
 Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA 
 Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA 
 Department of Medicine, Division of Hematology Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA 
 Department of Population Health Science and Policy, Center for Biostatistics, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA 
 Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA 
10  Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Sema4, A Mount Sinai venture, Stamford, CT, USA; Department of Medicine, Division of Hematology Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA 
Pages
1-12
Publication year
2018
Publication date
Aug 2018
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2096531758
Copyright
© 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.